IBM announced today that it has acquired two startups, Explorys and Phytel, to beef up its health-focused data-analytics efforts.
The news comes as IBM makes a concerted push in health care. In addition to announcing the acquisitions, IBM today also announced a new Watson Health unit.
Both startups provided cloud technologies. IBM did not disclose the terms of either of the acquisitions.
Un consorcio de empresas vascas, liderado por Onkologikoa, trabaja en la generación de un sistema informático inteligente que permita a los profesionales de la salud aprender de su propia práctica y optimizar los resultados de los tratamientos.
Uno de los grandes problemas a los que se enfrenta el avance de los tratamientos médicos es la imposibilidad de aprender con el paso del tiempo sobre la eficacia real de los mismos. Esto es debido a que los sistemas de información sanitaria no permiten recoger sistemáticamente el resultado de los tratamientos aplicados.
Last week, Cellular Dynamics International CEO Bob Palay described the $307 million acquisition of his company by Fujifilm as a union of two businesses that “share a common strategic vision for achieving leadership in the field of regenerative medicine.”
Every year, 1 million people die from malaria, more than 4 million from respiratory infections, 3 million from intestinal infections and 5 million due to AIDS and tuberculosis. Also, other sexually transmitted and parasitic infections in tropical regions are responsible for hundreds of thousands of deaths. Over 95% of these deaths occur in developing countries, as pointed out in the scientific articleDiagnostics for the Developing World, published in Nature Reviews in 2004. “Simple, accurate and stable diagnoses are essential to combat these diseases.
n the increasingly active genetic testing space, Natera is trying to lead the pack by harnessing its testing capabilities. And it has plenty of money to do so, after announcing a $55.5 million round of funding led today by Sofinnova Ventures and a group of crossover investors, including Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners, and OrbiMed Advisors.
Si un médico o investigador del Hospital Universitario La Paz quiere desarrollar una prueba o incorporar una nueva tecnología tiene un nuevo socio a quien pedirlo. El gigante alemán Siemens y la clínica madrileña acaban de firmar un acuerdo por el que esta institución se convierte en un centro de referencia internacional para esta compañía. Por su parte, la empresa se beneficiará de los conocimientos de los profesionales españoles para ensayar las innovaciones que más tarde llegarán al mercado.
San Diego’s aTyr Pharma has gotten all dressed up, but what’s the big occasion?
The biotherapeutics company said yesterday it recently raised $76 million in Series E financing to advance its program in physocrine-based drugs for treating rare immune diseases. The latest round brings total financing for aTyr (pronounced a-tire) to at least $184 million in the 10 years since the company was founded.
Two global initiatives to address Familial Hypercholesterolaemia (FH), a cholesterol-related disease, were launched at the European Atherosclerosis Society's (EAS) conference in Glasgow this week.
Familial hypercholesterolemia, or FH, is a genetic disorder characterised by high cholesterol levels which can cause cardiovascular diseases, such as heart attacks and strokes.
Though researchers and medical experts are becoming increasingly aware of how widespread FH is, the condition is still largely unknown by the general public, and workers in the healthcare sector.
How bullish are big drugmakers on cancer immunotherapy these days? Take a read from the deal Novartis announced today with Berkeley, CA-based Aduro Biotech, which is getting a nine-figure check from the Swiss drug giant for an immunotherapy approach that hasn’t yet been tested in humans.
